Your browser does not support JavaScript!

Home    Search  

Results - Details

Search command : Author="Βαμβακάκη"  And Author="Μαρία"

Current Record: 11 of 72

Back to Results Previous page
Next page
Add to Basket
[Add to Basket]
Title Effect of selected anticoagulants on bone metabolism- an in vitro study
Alternative Title Επίδραση επιλεγμένων αντιθρομβωτικών στο μεταβολισμό των οστών -μια in vitro μελέτη
Author Καφαντάρη, Μελανθία
Thesis advisor Χατζηνικολαϊδου, Μαρία
Reviewer Αλπαντάκη, Καλλιόπη
Βαμβακάκη Μαρία
Abstract The use of anticoagulants is crucial for patients recovering from orthopedic surgery since with this prophylactic treatment, thromboembolism can be prevented. In order to do so, physicians, prescribe their patients different classes of anticoagulants. Initially, heparin was the first drug prescribed, but its correlation to bone fractures and other side effects, led on developing new drugs, with Low Molecular Weight Heparins (LMWHs) being discovered. Another class, also used in effectively treating thromboembolism is Vitamin K antagonists, but they are also linked to bone malfunction among others. Direct Oral Anticoagulants (DOACs) is the newest class, and is considered patient friendly, since its administration is oral and does not require intensive monitoring. Unfortunately, DOACs are merely studied regarding bone malfunctions, with the relevant studies showing contradicting results and being of restricted extent. In this study, there is an attempt to investigate the effect of DOACs on bone metabolism, by studying how DOACs affect bone differentiation of mouse derived pre-osteoblasts MC3T3-E1. Five drugs were chosen for assessment depending on their class, Fondaparinux, a synthetic pentasaccharide, Rivaroxaban and Apixaban, direct inhibitors of factor Xa, Dabigatran etexilate, a direct thrombin inhibitor and Enoxaparin, a LMWH. For the exported results to be comparable, the same drug concentrations should be used, and for this reason, the administered dosage of the drugs was used to estimate the corresponding concentrations, ending up in 10-7, 10-6 and 10-5 M. The parameters chosen to be investigated were 1. cell viability, 2. enzymatic Alkaline Phosphatase (ALP) Activity, 3. Calcium mineralization, 4. total collagen secretion and 5. relative expression levels of SPP1 (osteopontin), SPARC (osteonectin) and BGLAP (osteocalcin) genes. According to the data collected, the drugs do not affect the cell viability and Calcium mineralization in the tested concentrations (10-7, 10-6, 10-5 M), and no significant variation was found in the expression levels of SPP1 and BGLAP. On the contrary, ALP activity, total collagen secretion and expression levels of SPARC, were decreased compared to the control group indicating that all the drugs demonstrate an inhibitory effect on bone differentiation. Moreover, comparing the effect of the drugs, it becomes clear that Fondaparinux is the less affecting drug, with the milder decrease in ALP activity and collagen secretion and the most affecting is Dabigatran etexilate. Thought-provoking are the results of Apixaban and Rivaroxaban, two drugs that are both direct factor Xa inhibitors and, thus, were expected to influence bone formation in a similar manner, but Apixaban affects the most the ALP activity, and Rivaroxaban the secreted collagen.
Language English, Greek
Subject Anticoagulants drugs
Direct oral
Low molecular weight heparins
Αντιθρομβωτικά φάρμακα
Ηπαρίνες χαμηλού μοριακού βάρους
Οστεογένεση
Issue date 2022-07-29
Collection   School/Department--School of Medicine--Department of Medicine--Post-graduate theses
  Type of Work--Post-graduate theses
Permanent Link https://elocus.lib.uoc.gr//dlib/3/c/3/metadata-dlib-1663676248-845707-26313.tkl Bookmark and Share
Views 304

Digital Documents
No preview available

No permission to view document.
It won't be available until: 2025-07-29